Levi A. Garraway

Affiliations: 
Biology: Medical Sciences, Division of Harvard University, Cambridge, MA, United States 
Area:
Molecular Biology, Bioinformatics Biology
Google:
"Levi Garraway"

Children

Sign in to add trainee
Jeff Meng grad student (Neurotree)
Eliezer M. Van Allen grad student (Neurotree)
Sylvan C. Baca grad student 2013 Harvard
Nikhil Wagle post-doc
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Carpten JD, Fashoyin-Aje L, Garraway LA, et al. (2021) Making cancer research more inclusive. Nature Reviews. Cancer
Lo JA, Kawakubo M, Juneja VR, et al. (2021) Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Science Translational Medicine. 13
Zaidi SH, Harrison TA, Phipps AI, et al. (2020) Landscape of somatic single nucleotide variants and indels in colorectal cancer and impact on survival. Nature Communications. 11: 3644
Izar B, Tirosh I, Stover EH, et al. (2020) A single-cell landscape of high-grade serous ovarian cancer. Nature Medicine
Liu D, Schilling B, Liu D, et al. (2020) Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nature Medicine
Wander SA, Cohen O, Gong X, et al. (2020) The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer. Cancer Discovery
. (2020) Pan-cancer analysis of whole genomes. Nature. 578: 82-93
Nusinow DP, Szpyt J, Ghandi M, et al. (2020) Quantitative Proteomics of the Cancer Cell Line Encyclopedia. Cell. 180: 387-402.e16
Wander SA, Cohen O, Gong X, et al. (2020) Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC) Cancer Research. 80
Liu D, Schilling B, Liu D, et al. (2019) Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nature Medicine
See more...